Advaxis, Inc. (ADXS)

Teaching the Immune System to Fight Cancer™

The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Clinical Pipeline

Clinical Pipeline

Visit Advaxis Clinical Pipeline for more information on ADXS-HPV Clinical Program for HPV-associated cancers.

View Clinical Pipeline

Recent Scientific Presentation

Scientific Publications

Advaxis Presents Preliminary Data From a Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination With Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients.

View Presentation

Investors

More Information

Upcoming Event

2015 Jefferies Immuno-Oncology Summit

Boston Harbor Hotel, Boston, MA